Journey Medical Corp (DERM) income statement
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3033% below fair value
$3.69−0.21 (-5.38%)
Close on Nov 18, 2026Market cap $104.15MP/E –Yield –
Journey Medical Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 65.5%
- Operating margin
- -4.4%
- Net margin
- -9.0%
- Return on equity, FY2025
- -44.0%
Financial strength
- Current ratio
- 1.59
- Debt to equity
- 0.79
- Debt to assets
- 25.9%
- Cash to current liabilities
- 56.0%
Valuation
- P/E ratio
- –
- Price to sales
- 1.53
- Price to book
- 3.24
- Dividend yield
- –
See a number that looks wrong?